Boston Scientific (BSX) Receivables (2009 - 2026)

Boston Scientific has disclosed Receivables across 18 years of filings, most recently posting $3.2 billion for Q2 2026.

• In Q2 2026, Receivables rose 8.78% year-over-year to $3.2 billion; the TTM figure through Jun 2026 stood at $3.2 billion (up 8.78% YoY), while the FY2025 annual figure was $3.1 billion, up 14.66% from the prior year.
• Receivables came in at $3.2 billion for Q2 2026 at Boston Scientific, up from $3.2 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.2 billion in Q2 2026 to a low of $2.0 billion in Q1 2022.
• Average Receivables over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2024.
• Year-over-year, Receivables increased 17.25% in 2024 and climbed 8.78% in 2026.
• Over 5 years, Receivables stood at $2.1 billion in 2022, then climbed by 12.46% to $2.3 billion in 2023, then advanced by 14.07% to $2.7 billion in 2024, then climbed by 14.66% to $3.1 billion in 2025, then advanced by 4.12% to $3.2 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $3.2 billion in Q2 2026, $3.2 billion in Q1 2026, and $3.1 billion in Q4 2025.